Rubicon Research Ltd
Rubicon Research Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #17 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Rubicon Research reported a strong revenue growth of 39% year-on-year in Q2 FY '26. Revenue growth of 39% year-on-year reported in Q2 FY '26, driven by new product launches and growth in existing products.
From Rubicon Research Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Rubicon Research reported a strong revenue growth of 39% year-on-year in Q2 FY '26.
- The company anticipates continued sustained revenue traction, with a diverse product portfolio reducing dependence on top products.
- Growth is driven by new product launches, continued ramp-up of existing products, and expansion in branded specialty products.
- Expansion plans include ramping up manufacturing capacity, notably the Pithampur plant expected to be operational by mid-2026 and fully contributing by early 2027.
- Focus on regulated markets, primarily the U.S., with additional filings in rest-of-world markets, though significant revenue currently from the U.S.
- Commercialization rate of approved products is strong at 93%, supporting ongoing growth.
2 more points from Rubicon Research Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rubicon Research Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Rubicon is operationalizing the Pithampur manufacturing facility by mid-2026 (May 2026), which is expected to ease current outsourcing constraints and support future revenue growth.
- The Pithampur plant is USFDA-approved and will enable tech transfer of existing products, aiding quicker approvals and ramp-up of production from this site.
- The facility will initially focus on US market supply but plans to file for other regulated markets as opportunities arise.
- There were recent minority stake investments in companies linked to Rubicon’s pipeline strategy; specifics are undisclosed but align with long-term commercial growth over 5-8 years.
2 more points from Rubicon Research Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rubicon Research Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Rubicon Research Ltd said on order book & pipeline — free account, 30 seconds.
Rubicon Research Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹476 Cr, net profit ₹73 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rubicon Research Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharmachem Ltd (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rubicon Research Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rubicon Research Ltd Q2 FY26 results?
Rubicon Research reported a strong revenue growth of 39% year-on-year in Q2 FY '26. Revenue growth of 39% year-on-year reported in Q2 FY '26, driven by new product launches and growth in existing products.
What is Rubicon Research Ltd share price analysis?
Rubicon Research Ltd currently shows a neutral. The stock trades at a P/E of 105.5 with a market cap of ₹26,041 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rubicon Research Ltd planning capital expenditure?
Rubicon is operationalizing the Pithampur manufacturing facility by mid-2026 (May 2026), which is expected to ease current outsourcing constraints and support future revenue growth.
Keep Rubicon Research Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.